Literature DB >> 24752512

Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility.

Steven A Greenberg1.   

Abstract

INTRODUCTION: Recent studies have identified circulating immunoglobulin (Ig) G autoantibodies against cytoplasmic 5'-nucleotidase 1A (cN1A; NT5C1A) in patients with inclusion body myositis (IBM), whose detection provides for an IBM blood diagnostic test. Whether or not anti-cN1A autoantibody isotypes other than IgG are present in IBM has not previously been reported.
METHODS: Plasma and serum samples from 205 patients (50 with and155 without IBM) were studied for the presence of IgM and IgA, in addition to IgG, anti-cN1A autoantibodies using immunoblots and enzyme-linked immunoassays (ELISAs).
RESULTS: IgM, IgA, and IgG anti-cN1A autoantibodies were detected by ELISA with similar sensitivities (49-53%) and specificities (94-96%), but with differing patterns of autoantibody isotype presence. Combination assays of all 3 autoantibody levels improved diagnostic sensitivity to 76%.
CONCLUSIONS: In addition to previously recognized IgG anti-cN1A autoantibodies, IBM patients have circulating IgM and IgA anti-cN1A autoantibodies. Differing patterns of these isotypes may be present and useful for diagnosis.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  anti-cN1A antibodies; inclusion body myositis

Mesh:

Substances:

Year:  2014        PMID: 24752512     DOI: 10.1002/mus.24199

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  16 in total

1.  Sporadic inclusion body myositis: new insights and potential therapy.

Authors:  Pedro M Machado; Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Opin Neurol       Date:  2014-10       Impact factor: 5.710

2.  Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.

Authors:  Richard M Yeker; Iago Pinal-Fernandez; Lisa G Rider; Andrew L Mammen; Takayuki Kishi; Katherine Pak; Ira N Targoff; Frederick W Miller
Journal:  Ann Rheum Dis       Date:  2018-01-23       Impact factor: 19.103

3.  Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.

Authors:  N A Goyal; T M Cash; U Alam; S Enam; P Tierney; N Araujo; F H Mozaffar; A Pestronk; T Mozaffar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-04-09       Impact factor: 10.154

Review 4.  Update on muscle disease.

Authors:  J Witherick; S Brady
Journal:  J Neurol       Date:  2018-04-18       Impact factor: 4.849

Review 5.  Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies.

Authors:  Sarah L Tansley; Neil J McHugh
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

Review 6.  Immune-Mediated Neurological Disorders.

Authors:  Teerin Liewluck; Augusto Miravalle
Journal:  Curr Neurol Neurosci Rep       Date:  2015-09       Impact factor: 5.081

7.  Conflicting reports of anti-cytosolic 5'-nucleotidase 1A autoantibodies in juvenile dermatomyositis: comment on the article by Rietveld et al.

Authors:  Andrew L Mammen; Iago Pinal-Fernandez; Lisa G Rider
Journal:  Arthritis Rheumatol       Date:  2022-03-28       Impact factor: 10.995

Review 8.  Autoimmune Myopathies: Updates on Evaluation and Treatment.

Authors:  Emer R McGrath; Christopher T Doughty; Anthony A Amato
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 9.  Neuromuscular issues in systemic disease.

Authors:  Wolfgang Grisold; Anna Grisold
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 6.030

10.  Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis.

Authors:  Matteo Lucchini; Lorenzo Maggi; Elena Pegoraro; Massimiliano Filosto; Carmelo Rodolico; Giovanni Antonini; Matteo Garibaldi; Maria Lucia Valentino; Gabriele Siciliano; Giorgio Tasca; Valeria De Arcangelis; Chiara De Fino; Massimiliano Mirabella
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.